Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166473 | 0.76 | IGF1R (0.47) | TRPV1IGF1RTHRBMAPTALPG | |
| SCHEMBL12766044 | 0.71 | PTGS2 (0.60) | TRPV1MAPTALDH1A1POLB | |
| SCHEMBL6838195 | 0.70 | GPR35 (0.47) | ESR1MAPTALDH1A1 | |
| SCHEMBL29200153 | 0.69 | LTA4H (0.44) | ESR1LMNA | |
| SCHEMBL1250655 | 0.68 | TSHR (0.50) | ESR1MAPTALDH1A1 | |
| SCHEMBL29200149 | 0.67 | PTGS2 (0.42) | ESR1MAPTALDH1A1POLB | |
| SCHEMBL24506264 | 0.64 | NPC1 (0.42) | ESR1NPSR1 | |
| SCHEMBL13209836 | 0.64 | IGF1R (0.45) | TRPV1IGF1RTHRBMAPTALPG | |
| SCHEMBL20399497 | 0.63 | PTGS2 (0.45) | IGF1RMAPTALDH1A1POLB | |
| SCHEMBL8433981 | 0.63 | TRPA1 (0.46) | ESR1IGF1RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | LIGAND PHARMACEUTICALS INC | 2004-03-11 | — | — | US | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | RXRB, RXRG, RXRA | TRPV1 586/4885ESR1 440/4885IGF1R 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.